Table 5.
Demographic and clinical characteristics of ACT participants with Alzheimer’s disease neuropathologic change (ADNC) with and without co-occurring Lewy body disease (LBD) or vascular brain injury (VBI)*
| Characteristics† | ADNC only | ADNC+LBD | ADNC+VBI |
ADNC+LBD +VBI |
|---|---|---|---|---|
| Total autopsies, N | 68 | 18 | 103 | 25 |
| Age at death, mean (SD) | 89.1 (6.7) | 88.9 (5.8) | 90.6 (5.9) | 87.8 (6.3) |
| Female | 43 (63.2) | 7 (38.9) | 60 (58.3) | 13 (52.0) |
| Non-white | 5 (7.4) | 1 (5.6) | 7 (6.8) | 1 (4.0) |
| College graduate | 26 (38.2) | 9 (50.0) | 31 (30.1) | 11 (44.0) |
| History of stroke | 2 (3.4) | 1 (6.7) | 25 (26.9) | 1 (4.5) |
| APOE ε4 allele | 20 (33.3) | 6 (37.5) | 33 (34.4) | 12 (60.0) |
| Demented | 35 (51.5) | 14 (77.8) | 76 (73.8) | 17 (68.0) |
| Clinical AD dementia | 33 (94.3) | 10 (71.4) | 61 (80.2) | 14 (82.3) |
ACT, Adult Changes in Thought study
*
ADNC = moderate/frequent neuritic plaques & Braak stage III-VI; LBD = Lewy bodies in any brain region examined; VBI = gross infarcts and cortical microinfarcts.
†
N,% unless otherwise specified. Relative frequencies presented for complete data. Number of participants missing data: stroke=25 (11.7%), and APOE genotype=22 (10.3%).